Featured Articles

  1. Early Product Characterization De-Risks Biologics Development 6/12/2019

    The relationship between physicochemical profile and biological activity — and how this relationship affects clinical performance — is key to informed decisions, accelerated development, and risk reduction.

  2. Lipids CDMO Services: Custom Excipients Tailored To Your Needs 4/27/2026

    Advance your lipid‑based programs with a CDMO partner equipped to deliver customized excipients, proven scale‑up expertise, and reliable support from early development through commercialization.

  3. Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies 4/17/2026

    Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.

  4. From Fermentation To Vaccination 4/8/2026

    Non-animal-origin squalene is gaining momentum in vaccine adjuvants. See how fermentation-derived squalene delivers comparable performance, strong stability, and regulatory alignment.

  5. Microbial Integrity Of Sampling Systems After Multiple Actuations 4/6/2026

    Repeated sampling doesn’t have to mean increased contamination risk. See how microbial ingress testing demonstrates sterility integrity after up to 50 sampling actuations.

  6. Evaluation Of TFF Operating Control Strategies And Scalability 4/2/2026

    Gain insight into a comparison of TMP and permeate control strategies for viral vector TFF, highlighting impacts on flux, processing time, impurity removal, and scale-up predictability across development.

  7. Innovating Upstream Manufacturing For The Next Wave Of Gene Therapies 3/4/2026

    Explore a streamlined approach to transient AAV production, including yield improvements across serotypes, key transfection parameters, and practical guidance for scaling processes.

  8. How A Specialized CDMO De-Risks Complex API Development 2/24/2026

    Rising API complexity and AI-driven chemistry require specialized CDMOs with technical expertise in hazardous or chiral synthesis to successfully navigate the transition to GMP manufacturing.

  9. A CDMO Is The Nexus Between Green Chemistry And Commercialization 2/24/2026

    Modern R&D transforms sustainability from an optional add-on into a strategic optimization tool, enhancing cost-efficiency, speed to market, and process intensification for drug developers.

  10. Why Reshoring Is An Essential Strategy For ADC Supply Chain Security 2/24/2026

    Biotechs reshoring their supply chains to Western regions to mitigate risk and improve reliability require experienced partners to effectively manage these complex transitions.